Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 456-463

  Casonato, Alessandra ^a   Daidone, Viviana ^a   Padrini, Roberto ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

von Willebrand disease; von Willebrand factor; VWF half life; VWF propeptide; VWFpp ratio

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 13; DESMOPRESSIN; LAMININ; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; CELL ACTIVATION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME METABOLISM; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE;

BIOLOGICAL MARKERS; HALF-LIFE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SURVIVAL ANALYSIS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 81755171936     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281029     Document Type: Article

References (36)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998 67 395-424 (Pubitemid 28411134)
2. Ruggeri ZM. von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003 1 7 1335-1342
3. Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987 70 4 895-904 (Pubitemid 18022359)
4. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990 6 217-246
5. Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980 55 6 1056-1059 (Pubitemid 10063385)
6. Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/ von Willebrand factor protein on binding to platelets. Blood 1981 58 2 387-397 (Pubitemid 11047359)
7. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 1991 113 1 195-205 (Pubitemid 21909686)
8. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984 99 6 2123-2130 (Pubitemid 15181875)
9. Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation. EMBO J 1987 6 10 2885-2890
10. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A 1992 89 8 3531-3535
11. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost 2009 7 Suppl 1 24-27
12. Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem 2004 279 48 49982-49988 (Pubitemid 39577807)
13. Purvis AR, Gross J, Dang LT et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci U S A 2007 104 40 15647-15652 (Pubitemid 350035354)
14. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 1988 52 2 229-236 (Pubitemid 18043596)
15. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A 1987 84 7 1955-1959 (Pubitemid 17054128)
16. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994 83 12 3536-3544 (Pubitemid 24175543)
17. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986 46 2 185-190 (Pubitemid 16031685)
18. Borchiellini A, Fijnvandraat K, ten Cate JW et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996 88 8 2951-2958 (Pubitemid 26357375)
19. Usui T, Takagi J, Saito Y. Propolypeptide of von Willebrand factor serves as a substrate for factor XIIIa and is cross-linked to laminin. J Biol Chem 1993 268 17 12311-12316 (Pubitemid 23182381)
20. Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y. Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor. J Biol Chem 1989 264 11 6017-6020 (Pubitemid 19106666)
21. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991 266 32 21948-21955 (Pubitemid 121000273)
22. Casonato A, Sartorello F, Cattini MG et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003 101 1 151-156 (Pubitemid 36025901)
23. van Mourik JA, Boertjes R, Huisveld IA et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999 94 1 179-185 (Pubitemid 29300147)
24. Casonato A, Pontara E, Sartorello F et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002 99 1 180-184
25. Haberichter SL, Balistreri M, Christopherson P et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006 108 10 3344-3351
26. Haberichter SL, Castaman G, Budde U et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008 111 10 4979-4985
27. Casonato A, Gallinaro L, Cattini MG et al. Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. Transl Res 2010 155 4 200-208
28. Nossent AY, VAN Marion V, VAN Tilburg NH et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006 4 12 2556-2562 (Pubitemid 44741547)
29. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 69 6 1691-1695 (Pubitemid 17091627)
30. Gallinaro L, Cattini MG, Sztukowska M et al. A shorter von Willebrand factor survival in O blood group explains how ABO determinants influence plasma von Willebrand factor. Blood 2008 111 3540-3545
31. Sadler JE, Budde U, Eikenboom JC et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
32. Gézsi A, Budde U, Deák I et al. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost 2010 8 6 1273-1280
33. Sztukowska M, Gallinaro L, Cattini MG et al. von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 2008 143 1 107-114
34. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998 80 1 37-41 (Pubitemid 28353495)
35. Millar CM, Riddell AF, Brown SA et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008 99 5 916-924 (Pubitemid 351705309)
36. Casonato A, Gallinaro L, Cattini MG et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica 2010 95 8 1366-1372